Table 1.

Immunohistochemical markers expressed in the patient explant, the BCK4 cell line, and the BCK4 tumors; pure mucinous (placebo supplemented mice; mucinous) and mixed mucinous (E2 supplemented mice; mucinous and invasive breast carcinoma (IBC)/invasive lobular carcinoma (ILC) regions)

Antigen	Patient explant	BCK4 cells	BCK4 tumor
			Pure mucinous	Mixed mucinous
			Mucinous	Mucinous	IBC (ILC)
ER	++	+	+⊥	++	+++
PR	+	+	−	+	+++
AR	++	++	+	+	++
GR	nd	++	nd	nd	nd
Her2	1+	1+	1+	1+	1+
EGFR	−	nd	⊥	⊥	−
E-cadherin	< 1 %	−	−	−	−
p120 catenin	cyto/nuc	cyto	cyto/nuc	cyto	cyto
CK8/18	++	+++	+	+	++
CD44	++	+	⊥	⊥	+
CK5	−	−	−	−	−
CK14	nd	−	−	−	−
Ckit	nd	+	++	++	+
CD10	nd	++	+	⊥	⊥
p63	nd	++	+	⊥	⊥
αSMA	nd	++	++	++	++
Vimentin	nd	⊥	−	−	−
MAM-A	nd	nd	+	+	+⊥
ChromograninA	nd	+	+	⊥	−
Synaptophysin	nd	++	+	⊥	−
Muc2	nd	nd	+	+⊥	⊥
N-cadherin	nd	nd	+	+	−

Cellular staining designations are as follows: −, negative staining; ⊥, <5–10 % staining; +, >10–30 % staining; +⊥, >30–50 % staining; ++, >50–70 % staining; +++, >70–100 % staining; nd not determined, cyto/nuc cytoplasmic/nuclear expression, 1+ Her2 expression by FISH analysis